bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
bioAffinity Technologies reported that CyPath Lung sales rose more than 100% through Q3 2026 versus the prior year, with tests delivered climbing to over 1,620 from 775 through Q3 2025. The number of ordering physicians grew 89% year-over-year, while physicians who adopted the test in 2025 increased their utilization by 48%, pointing to both new adoption and deepening repeat usage.
Key figures
- Sales growth yoy
- more than 100%
- Tests delivered q3 2025
- 775
- Tests delivered q3 2026
- 1620
- Physician offices growth
- nearly 90%
- Ordering physicians growth q3
- 89%
- Existing physician usage growth
- 48%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.